This study investigates the effectiveness of a combination of two investigational medications, axitinib and nivolumab, in treating patients with a specific type of kidney cancer called TFE/translocation renal cell carcinoma. This type of cancer cannot be removed by surgery or has spread to other parts of the body. Axitinib is thought to stop tumor growth by blocking certain enzymes needed for cell growth. Nivolumab is a type of immunotherapy that uses monoclonal antibodies to help the immune system attack cancer cells and possibly prevent them from growing and spreading.

Participants in this study will receive axitinib and nivolumab. The study will compare these treatments to standard treatments like surgery, chemotherapy, or other forms of immunotherapy. Axitinib and nivolumab are given to see if they work better together than the usual treatments. Immunotherapy involves using substances that stimulate or restore the ability of the immune system to fight cancer.

• Who can participate: Adults diagnosed with unresectable or metastatic translocation morphology renal cell carcinoma can participate. They must have measurable disease and a life expectancy of at least 8 weeks.
• Study details: Participants will receive investigational medications to evaluate their combined effect on cancer. A placebo will not be used in this study.